Optical Coherence Tomography (OCT) in Retinal Vasculitis
Evaluation of the Utility of OCT Angiography in Assessing Vascular Perfusion in Retinal Vasculitis
1 other identifier
observational
12
1 country
1
Brief Summary
Retinal vasculitis is a sight-threatening inflammation that involves the blood vessels of the retina, the tissue that lines the inside of the eye. This inflammation may occur on its own or as a result of an infectious, cancerous, or inflammatory disorder. Optical coherence tomography (OCT) is an imaging technology that can perform non-contact cross-sectional imaging of retinal and choroidal tissue structure in real time. It is similar to ultrasound imaging, except that OCT measures the intensity of reflected light rather than sound waves. The purpose of this study is to see if non-invasive OCT technology can diagnose retinal vasculitis as well as the more invasive fluorescein angiography, which requires an injection of dye into the vein of an arm of a patient. The study will also compare the mapping of blood vessels (angiography) and loss of blood flow (ischemia) by fluorescein angiography and OCT.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jan 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 18, 2013
CompletedFirst Posted
Study publicly available on registry
November 29, 2013
CompletedStudy Start
First participant enrolled
January 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 23, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
August 23, 2018
CompletedFebruary 12, 2024
February 1, 2024
4.6 years
November 18, 2013
February 8, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Blood flow patterns in retinal vasculitis
To determine if identifying early changes in blood vessel patterns will aid in early diagnosis and treatment of retinal vasculitis. Total retinal blood flow will be measured in uL/min.
24 months
Secondary Outcomes (1)
Ischemia in retinal vasculitis
24 months
Study Arms (1)
Retinal Vasculitis Group
Up to 35 patients diagnosed with retinal vasculitis will be considered and evaluated for enrollment in this study.
Eligibility Criteria
This study will measure blood vessel pattern/flow changes in up to 35 patients with retinal vasculitis.
You may qualify if:
- Diagnosis of retinal vasculitis
You may not qualify if:
- Inability to give informed consent.
- Inability to complete the qualifying study tests within a 30 day period from date of enrollment
- Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant.
- A prior history of reaction to fluorescein or other dyes.
- A condition that, in the opinion of the investigator, would preclude participation in the study (e.g. unstable medical status including blood pressure, cardiovascular disease, and glycemic control).
- Blood pressure \> 180/110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, subject can become eligible.
- Systemic anti-vascular endothelial growth factor (VEGF) or pro-VEGF treatment within 4 months prior to treatment.
- Women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months due to unknown safety of fluorescein angiography.
- Prior panretinal photocoagulation (PRP) or focal laser that would alter the macular perfusion and retinovascular features.
- Inability to maintain stable fixation for OCT imaging.
- Other ocular condition is present such that, in the opinion of the investigator, may alter the retinal perfusion.
- An ocular condition is present that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study (i.e. cataract)
- Substantial cataract that, in the opinion of the investigator, is likely to decrease visual acuity by 3 lines or more (i.e. cataract would be reducing acuity to 20/40 or worse if the eye was otherwise normal).
- Media opacity or otherwise that would prevent either fixation or ability to obtain adequate images as determined by the examiner.
- History of major ocular surgery (including vitrectomy, cataract extraction, scleral buckle, any intraocular surgery, etc) within prior 4 months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
OHSU
Portland, Oregon, 97239, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Phoebe Lin, MD, PhD
Oregon Health and Science University
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Phoebe Lin, MD, PhD, Assistant Professor of Ophthalmology
Study Record Dates
First Submitted
November 18, 2013
First Posted
November 29, 2013
Study Start
January 1, 2014
Primary Completion
August 23, 2018
Study Completion
August 23, 2018
Last Updated
February 12, 2024
Record last verified: 2024-02